Health Care · Pharmaceutical Preparations

ACTU ACTUATE THERAPEUTICS, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 165293537 filings
Russell 2000

ACTU at a glance

ACTUATE THERAPEUTICS, INC. (ACTU, SEC CIK 1652935) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as November 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 7 institutional investment managers tracked by SignalX reported holding ACTUATE THERAPEUTICS, INC. (ACTU) shares worth $466,000 in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by SCHMITT DANIEL M on October 28, 2026 of 140,844 shares at $0.35 per share.
  • In the last 90 days, ACTU insiders reported 1 open-market purchase ($50K) and 0 open-market sales ($0) on Form 4, a net purchase of $50K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
1 buy · 0 sells
Net +$50K
13F holders
7 funds
$466K · −6 vs prior quarter
Latest 8-K
Oct 30, 2026
Item 3.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales generated
  • Operating margin not applicable, operating loss $3,439,087 vs $5,472,378 YoY
  • Worst expense category: R&D $1,811,601 vs $2,177,922, down $366,321
  • Cash $2,101,816; operating cash use $12,373,256 for nine months
  • October offering net proceeds $11,764,494; substantial doubt regarding going-concern status and additional funding needs

Risk Factors

  • No material changes identified in the 10-Q Risk Factors section versus the 2025 10-K
  • Liquidity risk: cash $2,101,816 and working-capital deficit $974,694, with substantial doubt about going-concern status
  • Capital-markets risk: funding needs persist despite $11,764,494 October offering net proceeds
  • Nasdaq compliance risk: noncompliance with $50 million MVLS and $1.00 minimum-bid requirements
  • Clinical-development risk: elraglusib advancement depends on FDA or EMA feedback and patient enrollment

AI summary of the ACTU 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 30, 2026Full analysis →

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule

  • Nasdaq deficiency: ACTU closed below the $1.00 minimum bid for 30 consecutive business days
  • No immediate delisting: Common stock continues trading on Nasdaq Global Market under ACTU
Filed Oct 28, 2026Full analysis →

Item 8.01: Other Events

  • Actuate Therapeutics priced a securities offering on October 27, 2026
  • Offering terms and proceeds require review of press release Exhibit 99.1

Item 1.01: Entry into a Material Definitive Agreement

  • $9.96 million net proceeds from sale of 30,985,900 shares and warrants, providing near-term funding
  • Offering structure: two shares plus one warrant at $0.71, implying substantial equity dilution for existing holders

Item EX-99.1: Item EX-99.1

  • $11.0M gross equity financing, supporting working capital and general corporate purposes
  • 30,985,900 shares issued with 15,492,950 immediately exercisable warrants, creating substantial dilution risk
Filed Jul 17, 2026Full analysis →

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule

  • Nasdaq MVLS deficiency after market value remained below $50 million from June 1–July 14, 2026
  • Common stock remains listed and trading on Nasdaq Global Market under ACTU

AI summaries of ACTU 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ACTU

Don't miss the next ACTU filing

  • Alerts as it files. A push when ACTU files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ACTU, by share count.
  • Ask anything. An AI agent that reads every ACTU filing and answers with sources.

ACTU alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
BIOS Fund I, LPAOct 28, 2026-
BIOS Fund I, LPAOct 28, 2026-
BIOS Fund I, LPAOct 28, 2026-
BIOS Fund I, LPAOct 28, 2026-
BIOS Fund I, LPAOct 28, 2026-
BIOS Fund I, LPAOct 28, 2026-
SCHMITT DANIEL MBuyOct 28, 2026$0.35
BIOS Fund I, LPAOct 28, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$25.0M-$25.2M-$22.5M
Net Income-$24.7M-$27.3M-$22.2M
Balance Sheet
Total Assets$3.0M$9.3M$14.0M
Equity-$99.6M$104K$7.9M
ROE24.8%-26189.1%-280.5%
Per Share
EPS$-17.24$-3.26$-1.06
Cash Flow
Operating CF-$21.6M-$21.8M-$19.2M

Source: XBRL data in ACTUATE THERAPEUTICS, INC. (ACTU)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ACTU share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ACTU shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 20267$466,000
Q2 202613$1.2M
Q1 202615$3.1M
Q4 202511$7.2M
Q3 202511$5.1M
Q2 202510$3.8M
Q1 20257$831,000
Q4 20241$114,000
Position changes: Q2 2026 → Q3 2026
Top Buyers
None this quarter.
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 75 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ACTU filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 13, 2026Analysis
4Nov 2, 2026--
4Oct 30, 2026--
8-KOct 30, 2026Analysis-
4Oct 30, 2026--
4Oct 29, 2026--
8-KOct 28, 2026Analysis-
10-QAug 14, 2026Analysis
4Aug 14, 2026--
8-KJul 17, 2026Analysis-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
8-KMay 22, 2026Analysis
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
10-QMay 14, 2026Analysis
8-KMay 11, 2026Analysis
8-KMay 6, 2026Analysis
4Apr 1, 2026--
4Apr 1, 2026--
4Apr 1, 2026--
10-KMar 26, 2026-

Related Health Care companies

All Health Care →

ACTU SEC filings: frequently asked questions

Are ACTU insiders buying or selling?

In the last 90 days, ACTUATE THERAPEUTICS, INC. (ACTU) officers, directors and 10% owners reported 1 open-market purchase worth $50,000 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ACTU stock?

As of September 30, 2026, the largest ACTUATE THERAPEUTICS, INC. (ACTU) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($307,000), Millennium Management ($70,000), BlackRock ($51,000), State Street Corp ($17,000), Northern Trust ($17,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What did ACTU report in its latest 8-K?

ACTUATE THERAPEUTICS, INC. (ACTU) filed an 8-K on October 30, 2026 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule). Nasdaq deficiency: ACTU closed below the $1.00 minimum bid for 30 consecutive business days.

What are the latest ACTU SEC filings?

ACTUATE THERAPEUTICS, INC. (ACTU) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on November 2, 2026.

What is ACTU's SEC CIK number?

ACTUATE THERAPEUTICS, INC. (ACTU)'s SEC Central Index Key (CIK) is 1652935. EDGAR lists every ACTU filing under that number.

Ask anything about ACTU

The research agent reads ACTU's filings, financials, insider trades and 13F holders, then answers with sources.